Comparative Pharmacology
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus LEVOCETIRIZINE DIHYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus LEVOCETIRIZINE DIHYDROCHLORIDE.
KETOTIFEN FUMARATE vs LEVOCETIRIZINE DIHYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
Levocetirizine is a selective antagonist of peripheral histamine H1 receptors, blocking histamine-induced allergic responses by inhibiting H1 receptor activation in the gastrointestinal tract, blood vessels, and respiratory tract.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
5 mg orally once daily in the evening.
None Documented
None Documented
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Terminal elimination half-life: 7-11 hours in adults. Clinically, this supports once-daily dosing; may be prolonged in renal impairment (creatinine clearance <30 mL/min).
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Renal: 85% as unchanged drug (70%) and metabolites (15%); fecal: 13%; biliary: minimal (<2%).
Category A/B
Category A/B
Antihistamine / Mast Cell Stabilizer
Antihistamine